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(They ask you about wine and gambling. Say, "In them is great sin and [yet, 
some] benefit for people. But their sin is greater than their benefit." And they 
ask you what they should spend. Say, "The excess [beyond needs]." Thus 
Allah makes clear to you the verses [of revelation] that you might give 
thought).     
      Quran, Surah 2 (Al-Baqara) : 219 
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ANALISIS METABOLOMIK DARAH DAN URIN UNTUK MENGENAL 
PASTI PENANDA BIOLOGI KEBERGANTUNGAN ALKOHOL 
ABSTRAK 
Penyalahgunaan alkohol boleh membinasakan kesihatan masyarakat dan 
mengakibatkan masalah sosial yang teruk.Kebergantungan alkohol merupakan fasa 
penyalahgunaan alkohol sebagai akibat pengambilan alkohol dalam kuantiti yang 
berlebihan dan sentiasa terdorong untuk mengambil alkohol secara 
berterusan.Kaedah sedia ada untuk mengenalpasti kebergantungan alkohol adalah 
melalui soal selidik dan beberapa penanda biologi.Malangnya, kedua-dua kaedah ini 
mempunyai sensitiviti dan spesifisiti yang rendah.Metabolomik adalah lapangan 
saintifik yang novel yang menyediakan kaedah novel untuk mengenalpasti 
kebergantunagn alkohol dengan menggunakan teknik sensitif and spesifik seperti 
resonans magnet nukleus (NMR).Tujuan kajian ini adalah mengenalpasti 
pencapjarian metabolit (“metabotype”) yang dapat membezakan antara 
kebergantunagn alkohol, peminum tetapi tidak bergantung pada alkohol dan individu 
bebas alkohol dengan meggunakan kaedah metabolomik.Kajian ini turut dikaji dalam 
kebolehulangan. Sampel darah dan urin dikumpul daripada 30 individu yang 
bergantungan kepada alkohol (purata umur: 45.7), 54 peminum sosial (purata umur: 
39.5) dan 60 kawalan (purata umur: 37.1). Plasma dipisahkan melalui pengemparan, 
kemudian sampel plasma dan urin dicampur bersama larutan tampan fosfat yang 
disediakan dengan melarutkan di-natrium hidrogen fosfat (Na2HPO4), natrium 
dihidrogen fosfat(NaH2PO4), natrium 3-( trimetilsilil)- propionat -2,2,3,3-d4 (TSP), 
natrium azida (NaN3) and deuterium oksida (D2O) seterusnya analisis melalui 
spektroskopi NMR dijalankan. Data dianalisis menggunakan analisis multivarian 
termasuk analisis komponen utama dan analisis perbezaan ortogon separa kuasa dua 
xviii 
 
terkecil (OPLS-DA) diikuiti regresilogistik univariate dan multivariat untuk 
membangunkan model bagi pengenalpastian penanda biologi AD.Manakala, analisis 
kebolehulangan menggunakan pekali kolerasi antara-kelas (ICC). 
 Kajian dalam  plasma, model OPLS-DA mendedahkkan 39 pembolehubah 
yang mempengaruhi  unjuran(VIPs) secara signifikan yang dapat membezakan antara 
kumpulan AD dengan peminum sosial  dan kawalan. Kesensitifan, kespesifikan dan 
kejituan model ini masing-masing  adalah 64.29%, 98.17% dan 91.24%. Manakala 
dalam urin, model OPLS-DA menunjukkan 59 VIPs yang membezakan secara 
signifikan antara AD daripada peminum sosial dan kawalan.  Kesensitifan, 
kespesifikan dan kejituan model ini masing-masing  adalah 86.21%, 97.25% 
and94.93%.  Analisis dalam plasma menggunakan regresi logistik univariat 
mendapati 9 puncak yang berkaitan secara signifikan dengan AD dengan nilai p  ≤ 
0.1. Seterusnya  analisis dalam regresi  logistik multivariat membuktikan 4 puncak 
secara signikan berkait dengan AD dengan luas permukaan koefisi lingkungan 
penerima (AUROC), 0.961 . Kesensitifan, kespesifikan dan kejituan model ini 
masing-masing  adalah 78.6%, 98.2% dan 94.2%. Manakala analisa dalam urin 
menggunakan regresi logistik univariate, 30 puncak dikenalpasti mempunyai kaitan 
signifikan dengan AD dengan nilai p  ≤ 0.1.  Analisis menggunakan PCA, mendapati 
5 PCs mempunyai kaitan yang signikan dengan AD. Kemudian melalui analisis 
regresi  logistik multivariate, mendedahkan 2 PCs yang mempunyai 18 puncak 
adalah berkait secara signifikan dengan AD dengan AUROC, 0.909. . Kesensitifan, 
kespesifikan dan kejituan model ini masing-masing  adalah 65.5%, 99.1%and92%. 
 
xix 
 
 Melalui kajian ini, aplikasi teknik metabolomik menggunakan plasma dan 
urin dapat membezakan antara individu kebergantungan alkohol , peminum sosial 
dan kawalan. Metabolomik berdasarkan resonans magnetik nukleus dapat 
mengenalpasti penanda biologi yang novel dalam plasma dan urin bagi diagnosis AD 
untuk kegunaan masa hadapan. 
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METABOLOMICS ANALYSIS OF BLOOD AND URINE TO IDENTIFY 
ALCOHOL-DEPENDENCE BIOMARKERS 
ABSTRACT 
 Alcohol misuse is a ravaging public health and social problem. Alcohol-
dependence (AD) is a phase of alcohol misuse in which the drinker consumes 
excessive amount of alcohol and have a continuous urge to consume alcohol. The 
current methods of alcohol dependence diagnosis are questionnaires and some 
biomarkers. However, both methods lack specificity and sensitivity. Metabolomics is 
a novel scientific field which may provide a novel method for the diagnosis of 
alcohol-dependence by using a sensitive and specific technique such as nuclear 
magnetic resonance (NMR). Our aim was to identify the metabolic fingerprint 
(metabotype) that is able to discriminate between AD, non-AD alcohol drinkers and 
controls using metabolomics approach. The reproducibility of the outcomes was also 
investigated. Blood and urine samples were collected from 30 alcohol-dependent 
(mean age: 45.7), 54 social drinkers (mean age: 39.5) and 60 controls (mean age: 
37.1). Plasma was separated by centrifugation, then both plasma and urine samples 
were mixed with phosphate buffer which was prepared by dissolving di-sodium 
hydrogen phosphate (Na2HPO4), sodium dihydrogen phosphate (NaH2PO4), sodium 
3-(trimethylsilyl)-propionate-2,2,3,3-d4 (TSP), sodium azide (NaN3) and deuterium 
oxide (D2O)and then analyzed using NMR spectroscopy. Data analysis was done 
using multivariate analysis including principal component analysis (PCA) and 
orthogonal partial least squarediscriminateanalysis (OPLS-DA) followed by 
univariate and multivariate logistic regression to develop a model to identify the AD 
biomarkers. The reproducibility was done using intraclass correlation coefficient 
(ICC). 
xxi 
 
 For plasma, the OPLS-DA model revealed 39 bins with VIP (variable 
influence on projection) value more than 1 significantly discriminated AD from 
social drinkers and controls. The sensitivity, specificity and accuracy of the model 
were 64.29%, 98.17% and 91.24% respectively. For urine, the OPLS-DA model 
revealed 59 bins with VIP value more than 1 significantly discriminated AD from 
social drinkers and controls. The sensitivity, specificity and accuracy of the model 
were 86.21%, 97.25% and94.93% respectively. In the univariate logistic regression 
analysis of plasma, 9 peaks were significantly associated with AD with the p value ≤ 
0.1. In the multivariate logistic regression analysis, 4 peaks were significantly 
associated with AD with area under the receiver operating coefficient (AUROC) 
0.961. The sensitivity, specificity and accuracy of the model were 78.6%, 98.2% and 
94.2% respectively. In the univariate logistic regression analysis of urine,30 peaks 
were significantly associated with AD with the p value ≤ 0.1. The PCA revealed 5 
PCs were significantly associated with AD. In the multivariate logistic regression 
analysis, 2 PCs which consisted of 18 peaks were significantly associated with AD 
with AUROC 0.909. The sensitivity, specificity and accuracy of the model were 
65.5%,99.1%and92% respectively. 
 In this study, we have shown that the applied plasma and urine metabolomics 
technique was able to differentiate between the alcohol-dependent and the social 
drinkers and the controls. Nuclear magnetic resonance based metabolomics was also 
able to identify novel biomarkers in plasma and urine which can be useful to 
diagnose AD in the future.  
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CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
1.0  Background 
1.1  The global burden of alcohol drinking 
 Alcohol is one of the most historical substances that has been misused by 
man until today. Alcohol drinking is a ubiquitous public health problem. Its 
detrimental effect does not only ravage the consumers but also their families and 
societies. The World Health Organization (WHO) reported 2.5 million deathsevery 
year due to the hazardous consumption of alcohol(IAS, 2013; WHO, 2011). The 
United States reported 24,518 death cases due to alcohol consumption in 2009, of 
which 15,183 of them died due to alcoholic liver cirrhosis(NCHS, 2009). Many 
studies have shown that the harmful effects of alcohol consumption is the highest 
compared to other illicit drugs(van Amsterdam & van den Brink, 2013).  Besides its 
harmful effect on vital organs such as liver and kidney(Lieber, 2003), alcohol also 
has negative effects on cognitive perception, mood and behavior. Alcohol 
intoxication usually leads to drastic and destructive behavior. This will create social 
problems to the community. It also increases the incidence of accidents, injuries and 
crimes(Couture, Brown, Tremblay et al., 2010; Vaaramo, Puljula, Tetri et al., 2012).  
 Alcohol consumption is estimated to be the third risk factor for disease 
burden(Lieber, 2003).It was reported that there are some caseswhere alcohol 
consumption causedimmune system impairment(Karavitis & Kovacs, 2011). 
Therefore, chronic alcohol consumers usually have high susceptibility to acquire 
fatal infections(Cheng & Currie, 2005; Romeo, Warnberg, & Marcos, 2010). 
2 
 
Moreover, it has a negative impact on the vascular system by causing hemorrhagic 
stroke, arrhythmia and high blood pressure(McKee & Britton, 1998; J. Rehm, Room, 
Graham et al., 2003). 
 
1.2 Alcohol consumption in Malaysia 
 In Malaysia, according to the WHO report in 2005, alcohol consumption has 
increased since 2001 with beer as the highest consumed type of alcohol (WHO, 
2005). 
A research that was conducted to investigate the effects of alcohol drinking and drug 
abuse on fatal road accidents in urban areas of Kuala Lumpur, between year 2006 
and year 2009, indicated that 23.3% of fatal drivers were positive to alcohol, 11% 
positive to drug abuse and 2.3% were positive to both(Norlen Mohamed, Batcha, 
Nurul Kharmila Abdullah et al., 2012). A recently published study, that aims to find 
the etiologies of liver cirrhosis in Malaysia, revealed that alcohol is the main cause of 
liver cirrhosis among Indian Malaysians, and the fourth cause of liver cirrhosis 
among Chinese Malaysians(Qua & Goh, 2011). Such scrutiny sheds light on the 
increasing harmful effects of chronic alcohol consumption in Malaysia. In fact, this 
requires a thorough investigation of possible solutions that can early prevent the 
devastating consequences of chronic consumption of alcohol. 
 
1.3 Organ damage induced by alcohol consumption 
 A growing body of literature has asserted the harmful effects of alcohol 
consumption to the vital organs. Although some studies advocated cardio protective 
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role of moderate alcohol consumption(Boto-Ordonez, Urpi-Sarda, Queipo-Ortuno et 
al., 2013; Wallerath, Poleo, Li et al., 2003), other studies contradicted this by 
indicating that the protective role is overvalued(Fillmore, Stockwell, Chikritzhs et 
al., 2007; Plunk, Syed-Mohammed, Cavazos-Rehg et al., 2013; van Amsterdam & 
van den Brink, 2013). Such contentious literature robustly defeat any suggested 
beneficial effect of alcohol in the prevention of cardiovascular diseases.  
 In addition to cardiovascular diseases (CVDs), previous studies have found 
that the average volume of alcohol consumption is positively correlated with liver 
cirrhosis, depression, gastric ulcer and osteoporosis(Aguilera-Barreiro Mde, Rivera-
Marquez, Trujillo-Arriaga et al., 2013; Fini, Salamanna, Veronesi et al., 2012; 
McKee & Britton, 1998; J. Rehm et al., 2003; van Amsterdam & van den Brink, 
2013). It was concluded that alcohol consumption causes malabsorption, oesophageal 
reflux and diarrhea(Bujanda, 2000).  Besides,alcohol drinkingalso reduces fertility in 
both males and females (van Amsterdam & van den Brink, 2013). The literature has 
asserted that different patterns of alcohol consumption is a risk factor of several types 
of cancer such as liver cancer, breast cancer, colon cancer, renal cell cancer and 
oropharyngeal cancer(Baan, Straif, Grosse et al., 2007; Bagnardi, Rota, Botteri et al., 
2013; Bujanda, 2000; Radoi, Paget-Bailly, Cyr et al., 2013; J. Rehm et al., 2003). A 
recent meta analysis that aims to investigate the association between light alcohol 
drinking and different types of cancer has concluded that light drinking is associated 
with oropharyngeal cancer, breast cancer and oesophageal cancer(Bagnardi et al., 
2013).  In other words, chronic alcohol consumption can lead to injury and then to 
subsequent failure of vital organs. This requires some effort to be made to encourage 
the avoidance of alcohol consumption. Moreover, the early identification of people 
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who might be under the harmful effects of chronic alcohol consumption will help to 
save their vital organs. 
1.4       Alcohol metabolism in human 
 The alcohol is metabolized in the human body to acetaldehyde using three 
enzymes. These enzymes are alcohol dehydrogenase (ADH), cytochrome P450 
(CYP2E1) and catalase, which work by oxidizing ethanol to acetaldehyde. After that, 
the acetaldehyde will be metabolized to acetic acid by acetaldehyde dehydrogenase 
(ALDH). These two steps of metabolizing ethanol to acetic acid will increase the 
ratio of NADH/NAD+ ratio (Zakhari, 2006). 
 
 
Figure 1.1: Ethanol metabolism in human body 
 
1.5 Alcohol-dependence (AD) 
The National Health Committee, Wellington-New Zealand, in their 
guidelines for recognizing, assessing and treating alcohol and cannabis abuse in 
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primary care, has adapted a definition for alcohol dependence (AD) based on the 
American Psychiatric Association's classification system (DSM-IV), as the 
following(BPAC, 2010; "Guidelines for Recognising, Assessing and Treating 
Alcohol and Cannabis Abuse in Primary Care," 1999): 
"A maladaptive pattern of alcohol use leading to clinically significant impairment or 
distress".  
 This distress has many symptoms, such as a desire to drink more amounts of 
alcohol to attain intoxication effect, spending a lot of time either consuming alcohol 
or recovering from it, refraining fromsocial life activities, searching for events or 
places that will include drinking alcohol, making ineffective efforts to cut down 
alcohol consumption and having physical disorders after reducing the amount of 
consumed alcohol such as  tremors, anxiety, hallucination, nausea and 
vomiting(BPAC, 2010; "Guidelines for Recognising, Assessing and Treating 
Alcohol and Cannabis Abuse in Primary Care," 1999). 
 Unfortunately, the data shows that when the habit of drinking alcohol starts 
earlier in age, the susceptibility to develop AD is higher(Grant & Dawson, 1997). It 
could be inferred that when individuals become known as alcohol dependent, they 
would already have gone through a long period of exposure to the detrimental effects 
of alcohol consumption and hence will suffer failure of some of their vital organs. As 
an early diagnosis of diseases will lead to an early start of treatment, early detection 
of AD is crucial for preventing organs failure. For instance, the early detection of AD 
might prevent the progression of liver injury to anirreversible phase. 
 AD can be treated by ALDH inhibitor such as disulfiram (Carroll, Nich, Ball 
et al., 1998), or by opioid antagonist such as naltrexone (Volpicelli, Alterman, 
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Hayashida et al., 1992), or by topiramate(Johnson, Ait-Daoud, Bowden et al.) in a 
standardized medication compliance management of AD. 
1.5.1 Current diagnosticmethods of alcohol-dependence (AD) 
 Currently, AD questionnaires are the main clinical methods to diagnose the 
disease in clinical practice. Some biomarkers can also be used to aid the diagnosis. 
As biomarkers are usually produced by the body in response to disease or organ 
injury(Kumar & Sarin), a group of biomarkers were deduced from studies which 
investigated the harmful effects of alcohol consumption on body organs(Adias, 
Egerton, & Erhabor, 2013; Freeman & Vrana, 2010; Litten, Bradley, & Moss, 2010). 
Therefore, the biomarkers of organ injury, such as liver injury, are used as 
biomarkers of AD as well(Adias et al., 2013).However, their specificity to AD is 
reduced because they are biomarkers of organ injury regardless of the cause of 
injury(Adias et al., 2013; Freeman & Vrana, 2010). These biomarkers may lead to a 
confusionof diagnosis of AD with other diseases, such as non-alcoholic liver 
cirrhosis(Litten et al., 2010).  
1.5.1.1 AD questionnaires 
 Several questionnaires have been developed to indicate alcohol dependence 
diagnosis. The commonly used questionnaires are the alcohol use disorders 
identification test (AUDIT), the short version of AUDIT (AUDIT-C) and Michigan 
alcoholism screening test (MAST)(BPAC, 2010). These questionnaires consist of a 
set of questions that can differentiate between harmful and dependent alcohol 
consumption, and predict the leading risk factors of some diseases associated with 
alcohol consumption. 
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 The main drawback of AD diagnostic questionnaires is their subjective nature 
of measurement. They may not provide an actual estimation of an individuals' 
alcohol consumption due to the denial and under reporting of the regular consumed 
amount of alcohol. Moreover, there are limitations in the validations of these 
questionnaires due to the lack of standard questionnaires or definite diagnostic tool to 
be used as validation reference(Kroke, Klipstein-Grobusch, Hoffmann et al., 2001). 
1.5.1.2 Biomarkers 
 Biomarkers are biological indicators of a specific medical condition or 
disease which can be tested or measured by using lab tools. The National Institute of 
Health (NIH)Biomarkers Definitions Working Group had defined a biomarker as " a 
characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes or pharmacologic responses to a 
therapeutic intervention" (NIH Biomarkers Definitions Working Group, 
2001)(Freeman & Vrana, 2010). For example, the increase in serum creatinine level 
and consequently the decrease in creatinine clearance are used as biomarkers to 
diagnose and monitor renal diseases(Duncan, Heathcote, Djurdjev et al., 2001; 
Myers, Miller, Coresh et al., 2006).  
 The second method to diagnose AD is by testing AD biomarkers in biofluids. 
In fact, studies that were conducted to investigate the mechanisms of alcohol induced 
organ damage have found several mechanisms/pathophysiology of injuries involving 
certain biomarkers. For example, the rise of liver enzymes such as Alanine 
Aminotransferase (ALT), Aspartate aminotransferase (AST) and Gamma 
Glutamyltransferase (GGT) in AD individuals was obviously an indicator of alcohol 
induced liver injury(Adias et al., 2013). These differences in the levels of AST and 
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GGT in AD individuals compared to their abstainers had been found to be significant 
in several studies(Adias et al., 2013; Quaye, Nyame, Dodoo et al., 1992).The altered 
level of inflammatory mediators such as (cytokines) due to alcohol consumption had 
been correlated with the harmful effects of alcohol on bone, lung, liver and other 
tissues(Birkedal-Hansen, 1993; Fini et al., 2012; N., Freeman, & Vrana, 2011). 
Furthermore, as coagulating factors are synthesized in the liver, a study has 
concluded that prothrombin time (PT) and activated partial thromboplastin time 
(APTT) are significantly elevated in AD individuals (Adias et al., 2013).  
 Therefore, today it is a common practice to use blood and urine biomarkers of 
organ damage to diagnose AD. There are many biomarkers that have been 
investigated in research to diagnose AD such as Gamma glutamyl transferase (GGT), 
Mean Corpuscular Volume (MCV), Carbohydrate-Deficient Transferrin (CDT), 
Phosphatidylethanol (PEth), Ethyl Glucuronide (EtG) and Ethyl Sulfate 
(EtS)(Freeman & Vrana, 2010; George G. Harrigan, Maguire, & Boros, 2008; John 
C. Lindon, Nicholson, & Holmes, 2007 ; Litten et al., 2010; Rinck, Frieling, Freitag 
et al., 2007). 
Gamma glutamyl transferase (GGT) is available in cell membranes of the 
tissues of some organs such as liver, kidney, spleen, pancreas and heart(Litten et al., 
2010). Chronic alcohol consumption results in inflammation and necrosis of these 
cells, consequently this might increase the leakage of GGT from the destroyed cells 
(especially hepato-cells) thereby leading to an elevation in serum GGT(Litten et al., 
2010; Tavakoli, Hull, & Michael Okasinski, 2011).GGT has a long window of 
assessment, it remains elevated for two to three weeks after alcohol cessation, and it 
takes two weeks to elevate after the relapsing of heavy drinking(BPAC, 2010).It has 
20% sensitivity and 65.2% specificity (Larkman, 2013). 
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The Mean Corpuscular Volume (MCV)is a measurement of the size of red 
blood cells. It is an indicator of the chronic use of alcohol rather than the acute 
intake(Tavakoli et al., 2011), as chronic use increases the size of red blood 
cells(BPAC, 2010).The level of MCV can remain high for several months after 
cessation (Litten et al., 2010). Compared to GGT,the sensitivity of MCV in women is 
greater than that in men(Conigrave, Davies, Haber et al., 2003). 
Carbohydrate-Deficient Transferrin (CDT) is the widely used AD biomarker 
in clinical practice. Transferrin is glycoprotein synthesized and released by the liver, 
and transports iron throughout the body. Regular high alcohol intake leads to a 
decrease in the number of carbohydrate residues (sialic acid) attached to transferrin, 
thereby increasing carbohydrate deficient sites(BPAC, 2010). Serum CDT elevates 
with  regular and heavy drinking(60-80 g per day) and usually returns to normal after 
two to three weeks of cessation(Stibler, 1991). Because of the improvement in CDT 
measurement methods, the sensitivity and specificity of its testing have increased. 
Therefore, the Food and Drug Administration (FDA) affirmed CDT as a biomarker 
of heavy alcohol consumption(Litten et al., 2010). 
Phosphatidylethanol (PEth) is a phospholipid formed by phospholipase D 
enzyme in the presence of ethanol. It remains elevated in the blood for one to two 
weeks after cessation of moderate to heavy alcohol intake(Stewart, Reuben, 
Brzezinski et al., 2009). The advantage of PEth is that it is more sensitive than other 
biomarkers as it is not affected by the liver state(Stewart et al., 2009). Although other 
biomarkers can be increased by non-alcohol liver diseases, PEth can be used to 
monitor alcohol consumption with hepatic disease(Litten et al., 2010). 
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Ethyl Glucuronide (EtG) is a direct metabolite of ethanol, as ethanol is 
conjugated in hepatic endoplasmic reticulum with glucuronic acid through 
glucuronosyltransferase enzyme into EtG. It can be measured in blood, urine and 
hair. Urine EtG is usually used rather than serum EtG due to the short half-life of 
serum EtG which is between 14-20 hours. Whereas, urine EtG can be detected up to 
several days. Currently, there are developed methods to measure EtG in hair and this 
will help to detect EtGfor several months after alcohol cessation(Litten et al., 2010).  
Ethyl Sulfate (EtS) is a metabolite of alcohol. It is yielded from the sulfate 
conjugation of alcohol by sulfo-transferase enzyme. It was discovered that there is a 
positive correlation between EtG and EtS in urine samples(Litten et al., 2010). 
1.5.1.2.1 Limitations of thecurrentAD biomarkers 
Although current AD biomarkers are being used to assist in making AD 
diagnosis, there are some limitations that hinder their uses. The drawbacks are 
mainly due to their low specificity and sensitivity which indeed lead to false 
diagnosis.  
 The AST and ALT are not specific to AD, they are usually used to screen 
liver damage regardless of the cause(Adias et al., 2013; Litten et al., 2010).The GGT 
is also not specific to AD. It can be elevated in non-alcoholic liver diseases, smoking, 
obesity, diabetes mellitus, age, nutritional factors and metabolic disorders(Adias et 
al., 2013; Litten et al., 2010). Moreover, GGT can be elevated by some medications 
such as barbiturates, anticonvulsants and anticoagulants(Litten et al., 2010). In fact, 
the low sensitivity and specificity will hinder the use of GGT, AST and ALT in the 
discrimination between alcoholic and non-alcoholic liver diseases.  
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 The MCV is elevated in both folate and vitamin B12 deficiencies, 
hypothyroidism, non-alcoholic liver diseases, hemolysis, and bleeding disorders. It 
can also be elevated in patients on treatment with medications that can induce bone 
marrow disorders and toxicity(Litten et al., 2010).  
 Though PEth has the advantage of being a specific biomarker of alcohol 
consumption and not affected by liver condition, it is limited by its lower 
differentiation ability between moderate and heavy drinkers(Stewart et al., 2009). 
Similarly, the EtG has its limitations as well. For example, if urine sample contains 
yeast, this will convert urine glucose to alcohol and then to EtG.This may lead to 
false positive results,especially of diabetic patients who have  high levels of glucose 
in urine(Litten et al., 2010).Moreover, washing the hair may remove EtG from hair 
shaft(Tavakoli et al., 2011).The EtG's window of assessment isbetween one to two 
days after alcohol cessation which is too short a time to detect AD. 
 The CDT sensitivity is similar to GGT, but with higher specificity. A recent 
study to evaluate and to compare the range of  AD biomarkers of a group of  heavy 
drinkers in Russia concluded that CDT might be the best biomarkers with 67% 
sensitivity and 71% specificity to detect a daily average alcohol consumption of 40g 
and above(McDonald, Borinskya, Kiryanov et al., 2013). However, the use of CDT 
as AD biomarker is hindered by the possibilities of false positives due to rare genetic 
transferrin variants, chronic end-stage liver disease, smoking, body weight, female 
gender, primary biliary cirrhosis and hepatocarcinoma(Litten et al., 2010). 
 In an approach to increase sensitivity and specificity of AD biomarkers, some 
combinations had been examined. The best suggested combination is CDT, GGT and 
MCV(Larkman, 2013; Litten et al., 2010). This combination might help in males and 
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females, heavy drinkers with or without liver diseases(Litten et al., 2010).Another 
combination is CDT and MCV which has been shown to improve sensitivity and to 
perform better than either one of the biomarkers alone. However, the risk of false 
diagnosis cannot be excluded(Tavakoli et al., 2011). 
 Nevertheless, there were some reports which stated that the  CDT, GGT and 
MCV are not reliable enough biomarkers of AD,the current practice uses them to aid 
questionnaires(Larkman, 2013).Therefore, a combination of biomarkers was 
suggested to limit but not rule out the risk of false diagnosis(Larkman, 2013). In 
general, the questionnaires and current AD biomarkers are not the perfect methods to 
diagnose AD accurately. Therefore, it is reasonable to argue that the finding is a 
more objective measurement of novel AD biomarkers that would be of an advantage. 
The diagnosis of AD patients will help to reduce AD patients' organ failure and 
social problems. It has been suggested that the use of any of the systems biology 
disciplines, particularly metabolomics, could eventually prove valuable in this 
area(Kumar & Sarin). 
 
1.6 Systems Biology 
 System biology is a biological approach that aims to investigate and to 
explore the complexity of  molecular perturbation by the comprehensive integration 
of different bio-databases of molecular, genetic and metabolic networks, and the 
individual interaction between the components of each network(Breitling, 2010; 
Kuster, Merkus, van der Velden et al., 2011; G. Louridas & Lourida, 2012; G. E. 
Louridas, Kanonidis, & Lourida, 2010). This can give an in-depth understanding of 
the medical condition and hence improvesdrug discovery and personalization of 
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therapy(G. Louridas & Lourida, 2012). In fact, the power of system biology is based 
on the concept that although the clinical phenotype of a molecular disturbance is not 
obvious, the consequent compensatory adaptation due to this disturbance will be 
reflected in the transcriptome, proteome or metabolome(Kuster et al., 2011). 
1.6.1 Disciplines of Systems Biology 
 Systems biology combines a group of (-omics) disciplines, particularly the 
main majoromics such as genomics, transcriptomics, proteomics and 
metabolomics.While genomics focuses on the genome sequencing, 
transcriptomicsstudies the transcription and expression of genes sets using gene 
expression microarrays or RNA sequencing (Cappola & Margulies, 2011; Piran, Liu, 
Morales et al., 2012). These expressions will yield proteins which can be measured 
by gel electrophoresis or mass spectrometry (MS). The biochemical modifications to 
proteins can reflect a state of specific medical conditions. Lastly, the metabolic 
process in cells and organs ends with the production of metabolites which constitute 
the metabolome or metabolic profile.Metabolomics aim to discover and measure the 
changes in metabolome. Each one of the systems biology disciplines has been found 
to give fingerprints of prognostic value in diagnosing diseases.However, 
metabolomics is the ultimate screen that reflects other omics in addition to 
environmental factors. The use of systems biology disciplines to diagnose 
complicated medical conditions such as cancer, cardiovascular diseases and liver 
disease, has the advantage of being less invasive and fast(Cappola & Margulies, 
2011; Piran et al., 2012).Figure1.1 shows how the systems biology disciplines help in 
the understanding of the pathophysiology of diseases and the pathways behind 
specific phenotypic manifestation of the disease. The figure shows that metabolomics 
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is the ultimate internal picture of systems biology which can reflect the preceding 
disciplines. 
 
 
 
 
 
 
 
Figure 1.1: The role of systems' biology disciplines (omics) in disease diagnosis, where 
metabolomics represents the ultimate biomarker for detection of the disease before the 
phenotypic manifestations (adapted from(Piran et al., 2012)).  
  
1.7 Metabolomics 
 Metabolomics (ormetabonomics in some literature) is one of the systems' 
biology disciplines which comes in a chaincircle after genomics, transcriptomics and 
proteomics. It deals with the identification and quantification of small molecular 
metabolites in the metabolic profile (metabolome) of the living organism(Corona, 
Rizzolio, Giordano et al., 2012; G. Louridas & Lourida, 2012). The metabolome of 
each organism is highly affected either byinternal or external environmental factors. 
Therefore, the variation in metabolomemight be associated witha particular 
phenotype, specific nutrition, drugsand diseases. This variation can be considered as 
the metabolic finger print or surrogate biomarkers of medical condition or disease.  
Metabolomicsalso helps in the ability to understand the pathways that lead to 
changes in the levels of body metabolites due to disease, drug and/or environmental 
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effect(George G. Harrigan et al., 2008).The reason for the use of metabolomics in the 
exploration of medical conditionsin recent medical approach is because it doesnot 
only reflect the variation in genetics, transcriptomics and proteomics which might be 
associated with the condition, but also the environmental factors associated with the 
condition (Gutiu, Andries, Mircioiu et al., 2010). Moreover, it can give a 
predictionof body response to these internal and external factors. This can help in 
drug discovery and personalization of therapy.Recent studies have used 
metabolomics analysis to identify novel biomarkers of diseases such as asthma, 
COPD, cancer, diabetes mellitus, cystic fibrosis and metabolic disorders (Hocquette, 
2005; Hunt & John, 2007; Montuschi, Paris, & Melck, 2009; Robroeks, Van Berkel, 
Dallinga et al., 2010).  
 The metabolomics analysis involves the identification and measurement of 
small molecularcompounds inbiological samplessuch as blood, urine, cerebrospinal 
fluids CSF, breath, seminal fluids and tissues. These small molecular compounds are 
metabolites. Thetechniqueinvolveschemometric studies of the spectroscopic data of 
instruments such as nuclear magnetic resonance (NMR)spectroscopy and mass 
spectrometer (MS)(John C Lindon, Nicholson, & Holmes, 2011). 
 There are two terms that are commonly used to describe the study of body 
metabolites which are metabolomics and metabonomics. Metabonomics is defined as 
the study of metabolic response of living organism to biological or genetic variation 
(Nicholson & Lindon, 2008), while metabolomics is defined as the exploration of all 
metabolites inside the living organism(Fiehn, 2001; R. Goodacre, Vaidyanathan, 
Dunn et al., 2004). The distinction between these two terms; metabolomics and 
metabonomicsremains controversial and both terms are being used interchangeably 
in the literature to refer to the same discipline.In this context we are going to use the 
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term metabolomics, however, we might also refer to some literature which used the 
term metabonomics instead for our literature review.  
1.8 Application of metabolomics in disease diagnosis 
 As the pathophysiological changes in the body are usually reflected on the 
metabolome, it can be inferred that different medical conditions can have their 
distinct metabolic finger print (metabotype)on the metabolome. The metabotype is a 
group of certain metabolites that, eitherby their presence or absence, increased or 
decreased concentration,are distinctive for a specific clinical status or 
disease(Semmar, 2012).Researchers have investigated the use of metabolomics 
techniques to explore different medical conditions, in particular the conditions which 
have no definitediagnosis or their clear-cut diagnosis which needfurther invasive 
procedures. 
 
1.8.1 Application of metabolomics techniques to identify novel-biomarkers of 
diseases 
 The aim of metabolomics studies is to find a metabotypewhich has diagnostic 
or classifying value among patients andto exploreand measure the metaboliteswhich 
will further assistin the diagnosis or classification(John C. Lindon et al., 2007 ). 
 Many metabolomics studies have been conducted on biological fluid samples 
to identify biomarkers of diseases such as liver disease, diabetes, asthma, cancer and 
critical illnesses(Serkova, Standiford, & Stringer, 2011; Wang, Zhang, Han et al., 
2012). These studies have identified metabotypes which are able to 
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discriminatepatients from their controls. Table 1.1presents examples of 
metabolomics studies to diagnose diseases. 
 Some of the metabolomics studies aim to investigate metabolic changes 
consequent to the exposure to environmental factors or toxin, such as smoking and 
other harmful substances. In an approach to explore the effects of smoking and 
smoking cessation, researchers have used metabolomics techniques to quantify 140 
metabolites in fasting serum of three groups, namely current smokers, non-smokers 
and quitters (who have quitted during the follow up period of the study) in a 
longitudinal analysis (Xu, Holzapfel, Dong et al., 2013). It was discovered that 21 
smoking related metabolites were significantly different from those of current 
smokers and non-smokers. Interestingly, the study discovered that 19 out of the 21 
metabolites were reversible in quitters (Xu et al., 2013). In another study aimed to 
study the systemic toxic effect of welding fumes on humans, Wei and colleagues 
used liquid and gas chromatography-MS to investigate the plasma metabolome of 
boilermakers pre-welding and post-welding fumes exposure in a two stage-study 
(Wei, Wang, Chang et al., 2013). The first stage (stage one) of the study was 
conducted in 2011 on 11 boilermakers. The second stage (stage two) was conducted 
in 2012 on 8 boilermakers, and five of them participated in stage one in addition to 
three new recruited boilermakers. The results showed that the high exposure to high 
metal welding fumes causes a decrease in the level of unsaturated fatty acids (Wei et 
al., 2013).  
 The aforementioned metabolomics studies are part of continually growing 
body of evidences on the preeminent role that metabolomics can play not only in 
diseases diagnosis, but also in the pathogenic understanding of diseases and variable 
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medical conditions. This will help to monitor, guide and evaluate the current therapy, 
and help to find new drug target for future drugs. 
 Hitherto, to our knowledge, there were no metabolomics studies that had been 
conducted in humans to identify biomarkers of chronic use of alcohol or AD.  
Therefore, we propose the use of metabolomics in this research to find novel 
biomarkers that can discriminate AD patients from their matched controls and their 
matched social drinkers. 
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Table 1.1: Examples of metabolomics studies to diagnose diseases 
Study Disease Analytical Method Specimen Findings 
Ibrahim et al.,2011  
(Ibrahim, Basanta, 
Cadden et al., 2011) 
Asthma GC-MS Breath Development of a discriminatory model which classifies asthma patients with accuracy of 86% 
Basanta et al.,2012  
(Basanta, Ibrahim, 
Dockry et al., 2012) 
COPD GC-MS Breath 
Development of a discriminatory model which discriminate 
COPD patients from their healthy controls with 85% sensitivity 
and 50% specificity 
Schicho et al.,2012 
(Schicho, 
Shaykhutdinov, Ngo et 
al., 2012) 
IBD 1HNMR 
Serum, 
Plasma and 
Urine 
Characterization of 44 serum, 37 plasma and 71 urine 
metabolites to differentiate between diseased and non-diseased 
individuals 
Motsinger-Reif et al., 
2013 (Motsinger-Reif, 
Zhu, Kling et al., 2013) 
Al-zheimer 
with 
Dementia 
LC-ECA 
GC-TOF MS CSF 
Identified biomarkers which discriminate Al-zheimer patients 
from their healthy controls 
Lewitt et al., 
2013  
(Lewitt, Li, Lu et al., 
2013) 
Parkinson’s 
disease 
(PD) 
UPLC and GC- MS CSF 
Identification of 19 compounds which were able to discriminate 
PD patients from similar age healthy controls with a false 
discovery level of 20% 
GC-TOF MS: gas chromatography-time of flight mass spectroscopy, CSF: cerebrospinal fluid, UPLC: ultra performance liquid chromatography, IBD: Inflammatory bowel disease, 
COPD: Chronic obstructive pulmonary disease, LC-ECA: liquid chromatography-electrochemical coulometric array 
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1.8.2 Using metabolomics to investigate alcohol consumption 
 There are metabolomics studies that investigated the effect of alcohol 
consumption by analysing biological samples of animals on alcohol-containing diets. 
Further, researchers started to explore this in humans. 
1.8.3 Using metabolomics to investigate alcohol consumption in animal models 
 There are some studies that used the metabolomics approach to study the 
pathogenesis of alcohol consumption in animal models and to find novel biomarkers 
of alcohol consumption. Most of these studies were oriented by expected 
consequences of alcohol's detrimental effect such as liver injury or alcoholic liver 
disease (Bradford, O'Connell, Han et al., 2008; Fernando, Kondraganti, Bhopale et 
al., 2010; Loftus, Barnes, Ashton et al., 2011).  
 Bradford and colleagues used 1H-NMR and MS metabolomics techniques to 
evaluate the metabolic profile of urine and liver extract samples of mice with alcohol 
induced liver injury (Bradford et al., 2008). The mice were divided into two groups, 
one was fed with isocaloric (control group) and the other group was fed with alcohol 
containing liquid diet (alcohol group) of which the steatohepatitis was confirmed by 
5-fold increase of serum ALT, 6-fold increase in liver injury score and the increase 
of lipid peroxidation in the liver. The 1H-NMR principal component analysis of both 
urine and liver extract showed obvious discrimination between the two groups. For 
instance, the lactate was high in both liver and urine of those mice in the alcohol 
group. N-oleoylethanolamine metabolite was found to be elevated as well. Both 
lactate and N-oleoylethanolamine indicated hypoxic injury of the liver. Tyrosine was 
found to be elevated which might reflect an alteration in metabolism due to alcohol. 
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Moreover, there was a decrease in the excretion of taurine (glutathione metabolite) in 
the urine of those mice in the alcohol group. Additionally, it was found that there was 
an increase in prostacycline inhibitor 7,10,13,16-docosatetraenoic acid which is vital 
in the regulation of platelets formation (Bradford et al., 2008).  
In another study, by using LC-MS metabolomics technique, Loftus and 
colleagues explored the metabolomics changes in non-polar metabolites of rodents' 
livers due to alcohol consumption (Loftus et al., 2011). The study was conducted on 
rats and mice fed with intragastric alcohol feeding model.  The analysis of liver 
derived samples revealed a significant increase of fatty acyls, fatty acid ethyl esters, 
in addition to octadecatrienoic acid and eicosapentaenoic acid metabolites (Loftus et 
al., 2011).  Similarly, but by targeting the lipidomic profile, Fernando and colleagues 
extracted lipids from the plasma and liver of rats fed with alcohol diets and their 
controls (Fernando et al., 2010).It was concluded from both 1H-NMR and 31P-NMR 
data analysis that a significant alteration in lipid metabolism was induced by alcohol 
consumption. 
 To the best of our literature review we have found that most of the 
metabolomics studies which assessed alcohol consumption in animal models, 
focused on specific organ injury, particularly liver injury. None of these studies 
aimed to find the biomarkers of chronic use of alcohol or AD.  
1.8.4 Using metabolomics to investigate alcohol consumption in humans 
 To date, there are few metabolomics studies that have been conducted to 
study the effects of alcohol consumption on human metabolome. Jaremek and 
colleagues investigated the effects of alcohol consumption on human serum 
metabolome(Jaremek, Yu, Mangino et al., 2013). Researchers compared the serum 
22 
 
metabolome of two groups, light (LD) and moderate to heavy drinkers (MHD). The 
results showed that 40 identified metabolites in males and 18 in females differed 
significantly in concentration between these two groups. Out of these metabolites, 10 
in males and 5 in females were specific metabolites to discriminate LD from MHD. 
The investigators concluded that alcohol consumption mostly affect metabolic profile 
classes of diacylphosphatidylcholines, lysophosphatidylcholines, ether lipids and 
sphingolipids. These results indicated that the stimulatory effect of alcohol 
consumption on acid sphingomyelinase (ASM) activity causes the accumulation of 
ceramide and a decrease of sphingomyelins(Jaremek et al., 2013). However, the 
study did not explore the metabolic variation associated with chronic use of alcohol 
or AD.Additionally, it did not investigate urine metabolomics which is non invasive 
compared to blood.  
 In another study, the researchers used 1H-NMR metabolomics technique to 
find serum metabolic finger print that discriminate alcoholic liver cirrhosis from 
hepatitis B virus liver cirrhosis (Qi, Tu, Ouyang et al., 2012). The investigators found 
that five metabolites were able to distinguish between the two different types of 
cirrhosis. Similar to the studies mentioned earlier, the study did not explore urine 
metabolic profile and did not look for metabolic finger print of chronic use of 
alcohol. 
 
1.9 Application of metabolomics to find novel biomarkers of ADin blood and 
urine samples 
 As metabolomics studies aim to find a specific metabolic fingerprint 
(metabotype) that is associated with a particular medical condition or 
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disease,samplinga suitable biological sample is required.Blood and urine samples are 
usually considered stable and less invasive biological sampleswhere urine is 
leastinvasive and easy to get in abundance as it is the waste product (Decramer, de 
Peredo, Breuil et al., 2008; Down, 2010; Griffiths, 2008; Vaidyanathan, Harrigan, & 
Goodacre, 2005; Want, Wilson, Gika et al., 2010). Therefore, researchers 
preferplasma, serum and urine in metabolomics studies.  
 
1.10 Using 1H-NMR spectroscopicinstrument in metabolomics 
 The proton nuclear magnetic resonance 1H-NMR is one of the main analytical 
tools that isbeing widely used in metabolomics, in addition to mass spectroscopy 
(MS) and fourier transform infrared spectroscopy (FT-IR) (Basanta et al., 2012; 
Lloyd, William Allwood, Winder et al., 2011; Schicho et al., 2012). It is being used 
increasingly in metabolomics recently because it has the advantage of quickly 
revealing the metabolic profile of the biological sample depending on the magnetic 
properties of the widely spread hydrogen atoms in the chemical structure of the 
metabolites(Dunn, Bailey, & Johnson, 2005). The concept that1H-NMR 
analysisprocesses rely on every compound or metabolite contains hydrogen atoms in 
different chemical structure forms that will give specific and different peaks in the 
NMR spectra when the compound enters the magnetic field. These peaks are 
characteristic for each compound(Dunn et al., 2005).This, with the help of a 
chemometricsoftware,will help to speculate the chemical structure of the unknown 
metabolites in the biological samples.Although the sensitivity of 1H-NMR is low 
when compared to MS (Silva Elipe, 2003), the1H-NMR analysis is less complex as 
the sample does not need a prior derivatization, extraction and separation as required 
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by MS (Clayton, Lindon, Cloarec et al., 2006). In addition, 1H-NMR acts as an 
independent instrument compared to MS which requires a separate instrument like 
GC or LC(Dunn et al., 2005). The 1H-NMR is able to analyze hundreds of samples 
per day and the sample can be reused for further analysis (Nicholson & Lindon, 
2008; Shulaev, 2006). Therefore, the1H-NMR is considered cheap and non 
destructivewhen compared to MS. Figure 1.2 illustrates a Google scholar based 
literature search for publications containing (metabolomics & NMR) and 
(metabonomics & NMR). The search showed an increase in the number of 
publications from a total of 67 articles in year 2000 to 5870 articles in 2014. This 
reflects the great interest in using NMR in metabolomics studies due to the simplicity 
of sample preparation and the rapidyield of results. 
 
 
Figure1.2: Literature search at Google scholar for publications of (metabolomics + 
NMR) and (Metabonomics + NMR) 
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